Small intestinal compared with colonic short-chain fatty acid delivery drives distinct systemic concentrations and endocrine responses in humans: a randomized, crossover trial.
Riet Rosseel, Greet Vandermeulen, Tessa Dehau et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, crossover trial investigated the effects of short-chain fatty acid (SCFA) delivery to the small intestine versus the colon in 28 healthy adults. Results showed that colonic delivery resulted in greater peptide YY (PYY) release (β = 111.46 pg/mL.h, P adj = 0.04), while small intestinal delivery led to higher circulating SCFA concentrations and increased glucagon-like peptide 1 (GLP-1) release (β = 16.00 pM.h, P adj = 0.03).
Key findings
- PYY release was greater after colonic delivery compared to small intestinal delivery (β = 111.46 pg/mL.h, P adj = 0.04).
- Circulating SCFA concentrations were highest after small intestinal delivery, with acetate at β = 360.33 μM.h, P adj < 0.001.
- GLP-1 release was higher after small intestinal delivery compared to colonic delivery (β = 16.00 pM.h, P adj = 0.03).
- SCFA administration reduced appetite more significantly for small intestinal delivery.
Why it matters
Understanding the differential effects of SCFA delivery sites can inform dietary interventions aimed at modulating gut health and metabolic responses, potentially influencing strategies for managing conditions like obesity and diabetes.